REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Yang, Li ^a,b   Shi, Tingyan ^a,c   Liu, Fei ^a,d   Ren, Chunxia ^a,d,e   Wang, Ziliang ^a,d   Li, Yingyi ^a,d   Tu, Xiaoyu ^a,d   Yang, Gong ^a,d   Cheng, Xi ^a,d  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA POLYMERASE; DNA POLYMERASE ZETA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG; BAX PROTEIN, HUMAN; BCL2 PROTEIN, HUMAN; DNA BINDING PROTEIN; DNA DIRECTED DNA POLYMERASE; MCL1 PROTEIN, HUMAN; REV3L PROTEIN, HUMAN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER TISSUE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; CERVICAL CANCER CELL LINE; CHEMOSENSITIVITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; REV3L GENE; UTERINE CERVIX CANCER; BIOSYNTHESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HELA CELL LINE; METABOLISM; UTERINE CERVICAL NEOPLASMS;

BCL-2-ASSOCIATED X PROTEIN; CISPLATIN; DNA-BINDING PROTEINS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; FEMALE; G1 PHASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; UTERINE CERVICAL NEOPLASMS;

EID: 84924942696     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120334     Document Type: Article

References (53)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S (2014) GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. doi: 10.1097/QAI.0000000000000279 PMID: 25216079
2. Burger H, Loos WJ, Eechoute K, Verweij J, Mathijssen RH, et al. (2011) Drug transporters of platinum-based anticancer agents and their clinical significance. Drug Resist Updat 14: 22-34. doi: 10.1016/j.drup.2010.12.002 PMID: 21251871
3. Lange SS, Takata K, Wood RD (2011) DNA polymerases and cancer. Nat Rev Cancer 11: 96-110. doi: 10.1038/nrc2998 PMID: 21258395
4. Lehmann AR, Niimi A, Ogi T, Brown S, Sabbioneda S, et al. (2007) Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Repair (Amst) 6: 891-899. PMID: 17363342
5. McCulloch SD, Kunkel TA (2008) The fidelity of DNA synthesis by eukaryotic replicative and translesion synthesis polymerases. Cell Res 18: 148-161. doi: 10.1038/cr.2008.4 PMID: 18166979
6. Albertella MR, Lau A, O'Connor MJ (2005) The overexpression of specialized DNA polymerases in cancer. DNA Repair (Amst) 4: 583-593. PMID: 15811630
7. Li Z, Zhang H, McManus TP, McCormick JJ, Lawrence CW, et al. (2002) hREV3 is essential for error-prone translesion synthesis past UV or benzo[a]pyrene diol epoxide-induced DNA lesions in human fibroblasts. Mutat Res 510: 71-80. PMID: 12459444
8. Shachar S, Ziv O, Avkin S, Adar S, Wittschieben J, et al. (2009) Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. EMBO J 28: 383-393. doi: 10.1038/emboj.2008.281 PMID: 19153606
9. Jansen JG, Tsaalbi-Shtylik A, Hendriks G, Verspuy J, Gali H, et al. (2009) Mammalian polymerase zeta is essential for post-replication repair of UV-induced DNA lesions. DNA Repair (Amst) 8: 1444-1451. doi: 10.1016/j.dnarep.2009.09.006 PMID: 19783229
10. Ho TV, Scharer OD (2010) Translesion DNA synthesis polymerases in DNA interstrand crosslink repair. Environ Mol Mutagen 51: 552-566. doi: 10.1002/em.20573 PMID: 20658647
11. Sharma S, Hicks JK, Chute CL, Brennan JR, Ahn JY, et al. (2012) REV1 and polymerase zeta facilitate homologous recombination repair. Nucleic Acids Res 40: 682-691. doi: 10.1093/nar/gkr769 PMID: 21926160
12. Gibbs PE, McGregor WG, Maher VM, Nisson P, Lawrence CW (1998) A human homolog of the Saccharomyces cerevisiae REV3 gene, which encodes the catalytic subunit of DNA polymerase zeta. Proc Natl Acad Sci U S A 95: 6876-6880. PMID: 9618506
13. Nelson JR, Lawrence CW, Hinkle DC (1996) Thymine-thymine dimer bypass by yeast DNA polymerase zeta. Science 272: 1646-1649. PMID: 8658138
14. Murakumo Y, Ogura Y, Ishii H, Numata S, Ichihara M, et al. (2001) Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7. J Biol Chem 276: 35644-35651. PMID: 11485998
15. Murakumo Y, Roth T, Ishii H, Rasio D, Numata S, et al. (2000) A human REV7 homolog that interacts with the polymerase zeta catalytic subunit hREV3 and the spindle assembly checkpoint protein hMAD2. J Biol Chem 275: 4391-4397. PMID: 10660610
16. Hara K, Hashimoto H, Murakumo Y, Kobayashi S, Kogame T, et al. (2010) Crystal structure of human REV7 in complex with a human REV3 fragment and structural implication of the interaction between DNA polymerase zeta and REV1. J Biol Chem 285: 12299-12307. doi: 10.1074/jbc.M109.092403 PMID: 20164194
17. Murakumo Y, Ogura Y, Ishii H, Numata S, Ichihara M, et al. (2001) Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7. Journal of Biological Chemistry 276: 35644-35651. PMID: 11485998
18. Brondello JM, Pillaire MJ, Rodriguez C, Gourraud PA, Selves J, et al. (2008) Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta. Oncogene 27: 6093-6101. doi: 10.1038/onc.2008.212 PMID: 18622427
19. Wang H, Zhang SY, Wang S, Lu J, Wu W, et al. (2009) REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy. Neuro Oncol 11: 790-802. doi: 10.1215/15228517-2009-015 PMID: 19289490
20. Kawamura K, O-Wang J, Bahar R, Koshikawa N, Shishikura T, et al. (2001) The error-prone DNA polymerase zeta catalytic subunit (Rev3) gene is ubiquitously expressed in normal and malignant human tissues. Int J Oncol 18: 97-103. PMID: 11115544
21. Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, et al. (2005) Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 65: 11704-11711. PMID: 16357182
22. Wu F, Lin X, Okuda T, Howell SB (2004) DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res 64: 8029-8035. PMID: 15520212
23. Xie K, Doles J, Hemann MT, Walker GC (2010) Error-prone translesion synthesis mediates acquired chemoresistance. Proc Natl Acad Sci U S A 107: 20792-20797. doi: 10.1073/pnas.1011412107 PMID: 21068378
24. Lin X, Trang J, Okuda T, Howell SB (2006) DNA polymerase zeta accounts for the reduced cytotoxicity and enhanced mutagenicity of cisplatin in human colon carcinoma cells that have lost DNA mismatch repair. Clin Cancer Res 12: 563-568. PMID: 16428501
25. Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, et al. (2010) Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc Natl Acad Sci U S A 107: 20786-20791. doi: 10.1073/pnas.1011409107 PMID: 21068376
26. Kikuchi S, Hara K, Shimizu T, Sato M, Hashimoto H (2012) Structural Basis of Recruitment of DNA Polymerase ζ by Interaction between REV1 and REV7 Proteins. Journal of Biological Chemistry 287: 33847-33852. PMID: 22859296
27. Okuda T, Lin X, Trang J, Howell SB (2005) Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol 67: 1852-1860. PMID: 15758147
28. Knobel PA, Kotov IN, Felley-Bosco E, Stahel RA, Marti TM (2011) Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia 13: 961-970. PMID: 22028621
29. Shi TY, Yang L, Yang G, Tu XY, Wu X, et al. (2013) DNA polymerase zeta as a potential biomarker of chemoradiation resistance and poor prognosis for cervical cancer. Med Oncol 30: 500. doi: 10.1007/s12032-013-0500-4 PMID: 23456618
30. Shi TY, Yang G, Tu XY, Yang JM, Qian J, et al. (2012) RAD52 variants predict platinum resistance and prognosis of cervical cancer. PLoS One 7: e50461. doi: 10.1371/journal.pone.0050461 PMID: 23209746
31. Cheng X, Yang G, Schmeler KM, Coleman RL, Tu X, et al. (2011) Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy. Gynecol Oncol 121: 323-327. doi: 10.1016/j.ygyno.2010.12.360 PMID: 21277011
32. Yang G, Chang B, Yang F, Guo X, Cai KQ, et al. (2010) Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 16: 3171-3181. doi: 10.1158/1078-0432.CCR-09-3171 PMID: 20423983
33. Yang G, Rosen DG, Zhang Z, Bast RJ, Mills GB, et al. (2006) The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103: 16472-16477. PMID: 17060621
34. Yang G, Rosen DG, Liu G, Yang F, Guo X, et al. (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16: 3875-3886. doi: 10.1158/1078-0432.CCR-10-0483 PMID: 20505188
35. Bemark M, Khamlichi AA, Davies SL, Neuberger MS (2000) Disruption of mouse polymerase ζ (Rev3) leads to embryonic lethality and impairs blastocyst development in vitro. Current Biology 10: 1213-1216. PMID: 11050391
36. Bhat A, Andersen PL, Qin Z, Xiao W (2013) Rev3, the catalytic subunit of Polzeta, is required for maintaining fragile site stability in human cells. Nucleic Acids Res 41: 2328-2339. doi: 10.1093/nar/gks1442 PMID: 23303771
37. Okada T, Sonoda E, Yoshimura M, Kawano Y, Saya H, et al. (2005) Multiple roles of vertebrate REV genes in DNA repair and recombination. Mol Cell Biol 25: 6103-6111. PMID: 15988022
38. Wittschieben J, Shivji MK, Lalani E, Jacobs MA, Marini F, et al. (2000) Disruption of the developmentally regulated Rev3l gene causes embryonic lethality. Curr Biol 10: 1217-1220. PMID: 11050392
39. Schenten D, Kracker S, Esposito G, Franco S, Klein U, et al. (2009) Polζ ablation in B cells impairs the germinal center reaction, class switch recombination, DNA break repair, and genome stability. The Journal of experimental medicine 206: 477-490. doi: 10.1084/jem.20080669 PMID: 19204108
40. Lange SS, Bedford E, Reh S, Wittschieben JP, Carbajal S, et al. (2013) Dual role for mammalian DNA polymerase zeta in maintaining genome stability and proliferative responses. Proc Natl Acad Sci U S A 110: E687-E696. doi: 10.1073/pnas.1217425110 PMID: 23386725
41. Wittschieben JP, Reshmi SC, Gollin SM, Wood RD (2006) Loss of DNA polymerase zeta causes chromosomal instability in mammalian cells. Cancer Res 66: 134-142. PMID: 16397225
42. Sonoda E, Okada T, Zhao GY, Tateishi S, Araki K, et al. (2003) Multiple roles of Rev3, the catalytic subunit of pol zeta in maintaining genome stability in vertebrates. EMBO J 22: 3188-3197. PMID: 12805232
43. Lin X, Howell SB (2006) DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 5: 1239-1247. PMID: 16731756
44. Varadi V, Bevier M, Grzybowska E, Johansson R, Enquist K, et al. (2011) Genetic variation in genes encoding for polymerase zeta subunits associates with breast cancer risk, tumour characteristics and survival. Breast Cancer Res Treat 129: 235-245. doi: 10.1007/s10549-011-1460-z PMID: 21455670
45. Zhang S, Chen H, Zhao X, Cao J, Tong J, et al. (2013) REV3L 3′UTR 460 T>C polymorphism in micro-RNA target sites contributes to lung cancer susceptibility. Oncogene 32: 242-250. doi: 10.1038/onc.2012.32 PMID: 22349819
46. Brondello JM, Pillaire MJ, Rodriguez C, Gourraud PA, Selves J, et al. (2008) Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta. Oncogene 27: 6093-6101. doi: 10.1038/onc.2008.212 PMID: 18622427
47. Pan Q, Fang Y, Xu Y, Zhang K, Hu X (2005) Down regulation of DNA polymerases kappa, eta, iota, and zeta in human lung, stomach, and colorectal cancers. Cancer Lett 217: 139-147. PMID: 15617831
48. Hicks JK, Chute CL, Paulsen MT, Ragland RL, Howlett NG, et al. (2010) Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links. Molecular and cellular biology 30: 1217-1230. doi: 10.1128/MCB.00993-09 PMID: 20028736
49. Wittschieben JP, Patil V, Glushets V, Robinson LJ, Kusewitt DF, et al. (2010) Loss of DNA polymerase ζ enhances spontaneous tumorigenesis. Cancer research 70: 2770-2778. doi: 10.1158/0008-5472.CAN-09-4267 PMID: 20215524
50. Okuda T, Lin X, Trang J, Howell SB (2005) Suppression of hREV1 expression reduces the rate at which human ovarian carcinoma cells acquire resistance to cisplatin. Mol Pharmacol 67: 1852-1860. PMID: 15758147
51. Wang Y, Huang JW, Calses P, Kemp CJ, Taniguchi T (2012) MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res 72: 4037-4046. doi: 10.1158/0008-5472.CAN-12-0103 PMID: 22761336
52. Sharma S, Shah NA, Joiner AM, Roberts KH, Canman CE (2012) DNA polymerase zeta is a major determinant of resistance to platinum-based chemotherapeutic agents. Mol Pharmacol 81: 778-787. doi: 10.1124/mol.111.076828 PMID: 22387291
53. Gueranger Q, Stary A, Aoufouchi S, Faili A, Sarasin A, et al. (2008) Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. DNA Repair (Amst) 7: 1551-1562. doi: 10.1016/j.dnarep.2008.05.012 PMID: 18586118